Authors: Symonds, W

Citation: W. Symonds, World petroleum at the crossroads, ENERGY J, 21(3), 2000, pp. 129-130

Authors: Drusano, GL D'Argenio, DZ Preston, SL Barone, C Symonds, W LaFon, S Rogers, M Prince, W Bye, A Bilello, JA

Citation: Gl. Drusano et al., Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir, ANTIM AG CH, 44(6), 2000, pp. 1655-1659

Authors: Kumar, PN Sweet, DE McDowell, JA Symonds, W Lou, Y Hetherington, S LaFon, S

Citation: Pn. Kumar et al., Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults, ANTIM AG CH, 43(3), 1999, pp. 603-608

Authors: Hughes, W McDowell, JA Shenep, J Flynn, P Kline, MW Yogev, R Symonds, W Lou, Y Hetherington, S

Citation: W. Hughes et al., Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children, ANTIM AG CH, 43(3), 1999, pp. 609-615

Authors: Deeks, SG Hellmann, NS Grant, RM Parkin, NT Petropoulos, CJ Becker, M Symonds, W Chesney, M Volberding, PA

Citation: Sg. Deeks et al., Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome, J INFEC DIS, 179(6), 1999, pp. 1375-1381